Estimation of the individual residual risk of cervical cancer after vaccination with the nonavalent HPV vaccine

Background: The nonavalent HPV (9vHPV) vaccine is indicated for active immunisation of individuals from the age of 9 years against cervical, vulvar, vaginal and anal premalignant lesions and cancers causally related to vaccine HPV high risk types 16, 18, 31, 33, 45, 52 and 58, and to the HPV low ris...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Hum Vaccin Immunother
Main Authors: Petry, Karl-Ulrich, Bollaerts, Kaatje, Bonanni, Paolo, Stanley, Margaret, Drury, Rosybel, Joura, Elmar, Kjaer, Susanne K., Meijer, Chris J. L. M., Riethmuller, Didier, Soubeyrand, Benoit, Van Damme, Pierre, Bosch, Xavier
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6067852/
https://ncbi.nlm.nih.gov/pubmed/29553886
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2018.1450125
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados